MX2019014687A - Oral pharmaceutical formulations of remogliflozin. - Google Patents

Oral pharmaceutical formulations of remogliflozin.

Info

Publication number
MX2019014687A
MX2019014687A MX2019014687A MX2019014687A MX2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A MX 2019014687 A MX2019014687 A MX 2019014687A
Authority
MX
Mexico
Prior art keywords
remogliflozin
release layer
pharmaceutically acceptable
immediate release
pharmaceutical formulations
Prior art date
Application number
MX2019014687A
Other languages
Spanish (es)
Inventor
Ulhas Dhuppad
Nitin Deshmukh
Krishna Sadaphal
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2019014687A publication Critical patent/MX2019014687A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an immediate release oral formulation of remogliflozin or pharmaceutically acceptable salts thereof administered in patients in need thereof, for the treatment of diabetes mellitus. The present invention further relates to a pharmaceutical formulation comprising synergistic combination of remogliflozin etabonate and metformin hydrochloride. In a preferred embodiment, the invention relates to a bilayer tablet comprising an immediate release layer and an extended release layer wherein the immediate release layer comprises remogliflozin etabonate or pharmaceutically acceptable salts thereof and the extended release layer comprises metformin or pharmaceutically acceptable salt thereof.
MX2019014687A 2017-06-08 2018-06-07 Oral pharmaceutical formulations of remogliflozin. MX2019014687A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721020166 2017-06-08
PCT/IB2018/054091 WO2018198102A1 (en) 2017-06-08 2018-06-07 Oral pharmaceutical formulations of remogliflozin

Publications (1)

Publication Number Publication Date
MX2019014687A true MX2019014687A (en) 2020-10-15

Family

ID=63919598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014687A MX2019014687A (en) 2017-06-08 2018-06-07 Oral pharmaceutical formulations of remogliflozin.

Country Status (5)

Country Link
KR (1) KR20200013719A (en)
CN (1) CN110753540A (en)
BR (1) BR112019026029A2 (en)
MX (1) MX2019014687A (en)
WO (1) WO2018198102A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162841A1 (en) * 2018-02-21 2019-08-29 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin for treatment of diabetes mellitus
MX2020008546A (en) * 2018-02-21 2021-01-08 Glenmark Pharmaceuticals Ltd Pharmacutical composition comprising remogliflozin and antidiabetic agent.
WO2020182792A1 (en) 2019-03-12 2020-09-17 Dsm Ip Assets B.V. Coated coacervate capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
EP2498758B1 (en) * 2009-11-13 2018-07-25 AstraZeneca AB Bilayer tablet formulations
CN103153288B (en) * 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin

Also Published As

Publication number Publication date
BR112019026029A2 (en) 2020-06-23
KR20200013719A (en) 2020-02-07
WO2018198102A1 (en) 2018-11-01
CN110753540A (en) 2020-02-04

Similar Documents

Publication Publication Date Title
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2015523407A5 (en)
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
JP2017506624A5 (en)
JP2019517542A5 (en)
MX2019012884A (en) Combination therapy.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2013011174A (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients.
MX2019014687A (en) Oral pharmaceutical formulations of remogliflozin.
PH12020551939A1 (en) Pharmaceutical composition comprising sglt-2 inhibitor and dpp-iv inhibitor
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
JP2020536121A5 (en)
EP3972432A4 (en) Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
JOP20190054B1 (en) Indazole compounds for use in tendon and/or ligament injuries
FI3600276T3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2018011293A (en) Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
PH12016502226A1 (en) Bicyclic derivatives and pharmaceutical composition including the same
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
JP2015515971A5 (en)
JOP20200005A1 (en) Pharmaceutical compositions